Kymriah (tisagenlecleucel; Novartis) Drug Profile 2019: A Cluster of Differentiation (CD)19-Targeted Genetically Modified Autologous T-cell Immunotherapy

News provided by

Jun 26, 2019, 18:45 ET

DUBLIN, June 26, 2019 /PRNewswire/ -- The "Kymriah" report has been added to ResearchAndMarkets.com's offering.

Kymriah (tisagenlecleucel; Novartis) is a cluster of differentiation (CD)19-targeted genetically modified autologous T-cell immunotherapy, comprised of a murine single-chain antibody fragment that binds CD19 and is linked to intracellular signaling domains from 4-1BB (CD137) and CD3 zeta.

The CD3 zeta component helps to initiate T-cell activation, whereas the 4-1BB costimulatory domain facilitates expansion and persistence of the cells. Upon binding to CD19-expressing cells, Kymriah transmits a signal to promote T-cell expansion, activation, and target cell elimination.

Analyst Outlook

Kymriah (tisagenlecleucel; Novartis) is the second autologous chimeric antigen receptor T-cell (CAR-T) therapy to be approved for use in diffuse large cell B-cell lymphoma (DLBCL), and will face strong competition from the first-to-market CAR-T therapy Yescarta (axicabtagene ciloleucel; Gilead).

The high cost of CAR-T treatment and logistical challenges surrounding manufacture of the regimen will remain a barrier to uptake. Kymriah will also face increasing competition from late-phase drugs targeting the relapsed/refractory settings, including ublituximab (TG Therapeutics/LFB Biotechnologies), umbralisib (TG Therapeutics/Rhizen), and late-phase CAR-T lisocabtagene maraleucel (Celgene).

Despite these challenges, the durable response rates and acceptable safety profile demonstrated by Kymriah treatment in heavily pretreated patients will ensure continued revenue increases over the forecast period.

Key Topics Covered:

OVERVIEW

Drug Overview
Product Profiles
Kymriah: Chronic lymphocytic leukemia (CLL)
Kymriah: NHL: Follicular lymphoma (FL)
Kymriah: NHL: Diffuse large B-cell lymphoma (DLBCL)

LIST OF FIGURES

The authors drug assessment summary of Kymriah for CLL
The authors drug assessment summary of Kymriah for CLL
Kymriah sales for CLL across the US and five major EU markets, by country, 2017-26
Kymriah for follicular lymphoma - SWOT analysis
The authors drug assessment summary of Kymriah for follicular lymphoma
The authors drug assessment summary of Kymriah for follicular lymphoma
Kymriah sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017-26
Kymriah for diffuse large B-cell lymphoma - SWOT analysis
The authors drug assessment summary for Kymriah in diffuse large B-cell lymphoma
The authors drug assessment summary for Kymriah in diffuse large B-cell lymphoma
Kymriah sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES

Kymriah drug profile
Trials of Kymriah for CLL
Kymriah for CLL - SWOT analysis
Kymriah drug profile
Kymriah Phase IIa trial in follicular lymphoma
Kymriah clinical trial data in follicular lymphoma
Kymriah sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Kymriah drug profile
Kymriah pivotal trial data in diffuse large B-cell lymphoma
Kymriah early-phase trial data in diffuse large B-cell lymphoma
Kymriah sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/g0ltid

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets